Related Experiment Video
Updated: Jun 28, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
WIP1 inhibition as a new therapeutic strategy for collapsing glomerulopathy
1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Abstract:
Collapsing glomerulopathy (CG) is an aggressive variant of focal and segmental glomerulosclerosis. Understanding the diverse mechanisms that can drive CG promises to uncover new therapeutic strategies. In this issue, Duret et al. identify WIP1 phosphatase as a therapeutic target for CG. Using genetic ablation and pharmacologic inhibition, they show that blockade of WIP1 activity is protective in 2 different mouse models of CG. This study highlights the complex interplay of glomerular signaling pathways in CG and offers hope for targeted therapies.
Insights
Researchers identified WIP1 phosphatase as a novel therapeutic target for collapsing glomerulopathy (CG), an aggressive kidney disease. Blocking WIP1 activity showed protective effects in mouse models, offering hope for new CG treatments.
Area of Science:
- Nephrology
- Molecular Biology
- Pathology
Background:
- Collapsing glomerulopathy (CG) is a severe form of focal and segmental glomerulosclerosis.
- Identifying novel therapeutic targets is crucial for managing CG progression.
Purpose of the Study:
- To investigate WIP1 phosphatase as a potential therapeutic target for collapsing glomerulopathy.
- To evaluate the efficacy of targeting WIP1 in preclinical models of CG.
Main Methods:
- Genetic ablation of WIP1 in mouse models of CG.
- Pharmacologic inhibition of WIP1 activity.
- Assessment of kidney pathology and function in treated mice.
Main Results:
- Blockade of WIP1 activity demonstrated protective effects in two distinct mouse models of CG.
- This suggests WIP1 plays a critical role in the pathogenesis of CG.
Conclusions:
- WIP1 phosphatase represents a promising therapeutic target for collapsing glomerulopathy.
- Targeting WIP1 offers a potential strategy for developing novel treatments for this aggressive kidney disease.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Direct Renin Inhibitors

